Selexis signs deal with Ganymed

Selexis SA, a Switzerland-based biotechnology company offering technologies and services to enable significantly improved drug discovery, development, and current Good Manufacturing Practice production, has signed a commercial license agreement with Ganymed Pharmaceuticals AG, a privately-held cancer antibody company headquartered in Mainz, Germany, for use of its technology for large-scale production of the latter's lead antibodies. These are said to have a unique specificity for a variety of solid cancers with high medical need and large market potential.

This commercial license agreement allows Ganymed to use a high performance cell line, developed by the firm's scientists using the Selexis SURE Cell Line Development platform, for the clinical and commercial production of a number of agents.